Several serum soluble membrane molecules have been described showing increased levels in psoriatic patients, some of them presenting a significant correlation with the Psoriasis Area and Severity Index (PASI) score, one of the most commonly used methods to evaluate and monitor disease severity. Aim of this study was to evaluate whether or not the serum levels of three different soluble membrane markers presented a behavior corresponding to the disease improvement after therapy. In 18 plaque-type psoriatic patients (median PASI score 36.2, range 24-42.5, median age 54, range 34-75 years), the serum levels of β-2-microglobulin, soluble interleukin-2 receptor and soluble intercellular adhesion molecule-1, evaluated by means of commercially available ELISA kits, showed a marked increase as compared to controls (20 normal subjects, 10 males and 10 females, median age 48.5, range 21-60 years) and significant changes were observed after 1 month of effective therapy (Cyclosporin A, CyA at doses of 3 mg/kg/die administered in oral capsules), able to significantly modify the patients PASI scores (from a median of 36.2, range 24-42.5, to a median of 5.9, range 2.7-7.4, p <0,001). Different mechanisms may be considered to explain these findings, the most probable being based on a possible long emilife of each individual molecule and on a suggested persistent activation of some cell lineages, also in the absence of clinical signs.
|Number of pages||3|
|Journal||Giornale Italiano di Dermatologia e Venereologia|
|Publication status||Published - 1995|
ASJC Scopus subject areas